


Developing an antiviral for enterovirus infections



CUR-N399
January 2025



Addressing a global need in respiratory health

Curovir is developing an antiviral for enterovirus aimed for preventing exacerbations in asthma and COPD.

Enterovirus drive 25% of exacerbations, that are associated with increased morbidity, mortality and very large societal costs. Yet no enterovirus antiviral exists.

CUR-N399 is a host-targeting, broad-spectrum antiviral ready to enter clinical phase 2.

Global burden and COPD costs



COPD affects
≈391M
every year

Is the
3rd leading cause
of death worldwide

causing
≈3M
deaths a year

directs costs
\$50
billion in US

COPD is one of **the leading causes** of emergency hospital admissions in many countries.

Costs associated with COPD are estimated to increase from **\$2.1 trillion** globally in 2010 to **\$4.8 trillion** 2030.

Approx **67%** of COPD patients are of working age, disease causing reduced productivity, early retirement and diminished tax revenues.

- **Exacerbations** are episodes of increased disease **symptoms**.
- **25%** of exacerbations are **considered caused by enterovirus**.
- Antivirals can reduce exacerbations.
- Exacerbations account for about 50% of the direct COPD costs.
- **38.8% of COPD patients** (151Mn) are considered “frequent exacerbators” and **target group for CUR-N399**.

Summary of clinical trials with CUR-N399


Randomised, double-blind, single-centre, placebo-controlled evaluating the safety, tolerability and PK of CUR-N399

1st trial Oral capsule



- Doses up to NOAEL evaluated and found safe
- Accumulation observed at repeated doses
- Longer $T_{1/2}$ than anticipated about 40h
- PK supports single dose treatment

2nd trial Buccal film



- Safe and tolerable at all doses evaluated (up to NOAEL)
- Gastrointestinal signs and headache were the most frequently reported adverse events
- Blood status showed no relevant changes: lipids, lymphocytes, albumin or liver enzymes
- PK comparable between buccal film and oral capsule (slightly higher exposure after buccal administration)

Next steps

Having completed phase 1, Curovir now plans for a Phase 2 trial to demonstrate efficacy in a rhinovirus challenge trial in patients with asthma. The trial is planned to be conducted 2025-2026.

Curovir seeks a financial or industrial partner to support the company in the future development.

Capital needed € 6 million

The company

Curovir is a privately held Swedish SME, fully owned by Claesson and Anderzén Group, a family office, with its business divided into real estate and other investments.

Curovir is a virtual organisation optimized for flexibility to meet needs as they appear.



Johan Claesson
Co-founder



Nina Lindblom
Clinical trials and
business development



Jacob Westman
Preclinical research and
development and IP

Collaborating partners / contractors :

